Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions.
Read More…
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone626-350-0537
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$21.36 million
Profitability
Miscellaneous
Employees123
Next Earnings Date11/4/2019 (Confirmed)
OptionableNot Optionable
Fulgent Genetics (NASDAQ:FLGT) Frequently Asked Questions
What is Fulgent Genetics' stock symbol?
Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."
How were Fulgent Genetics' earnings last quarter?
Fulgent Genetics Inc (NASDAQ:FLGT) released its quarterly earnings results on Monday, August, 5th. The company reported $0.02 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.04) by $0.06. The firm earned $8.42 million during the quarter, compared to analysts' expectations of $6.42 million. Fulgent Genetics had a negative return on equity of 4.71% and a negative net margin of 12.38%. View Fulgent Genetics' Earnings History.
When is Fulgent Genetics' next earnings date?
How can I listen to Fulgent Genetics' earnings call?
Fulgent Genetics will be holding an earnings conference call on Monday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for FLGT?
2 brokerages have issued 12-month target prices for Fulgent Genetics' shares. Their predictions range from $9.50 to $9.50. On average, they anticipate Fulgent Genetics' share price to reach $9.50 in the next twelve months. This suggests that the stock has a possible downside of 17.5%. View Analyst Price Targets for Fulgent Genetics.
What is the consensus analysts' recommendation for Fulgent Genetics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Fulgent Genetics.
Has Fulgent Genetics been receiving favorable news coverage?
News coverage about FLGT stock has trended somewhat positive on Sunday, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fulgent Genetics earned a news impact score of 0.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Fulgent Genetics.
Are investors shorting Fulgent Genetics?
Fulgent Genetics saw a drop in short interest in September. As of September 15th, there was short interest totalling 102,400 shares, a drop of 5.2% from the August 15th total of 108,000 shares. Based on an average daily volume of 70,100 shares, the short-interest ratio is currently 1.5 days. Approximately 1.6% of the company's stock are sold short. View Fulgent Genetics' Current Options Chain.
Who are some of Fulgent Genetics' key competitors?
Some companies that are related to Fulgent Genetics include RadNet (RDNT), Personalis (PSNL), Castle Biosciences (CSTL), Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS), OpGen (OPGN) and Aeon Global Health (AGHC).
What other stocks do shareholders of Fulgent Genetics own?
Who are Fulgent Genetics' key executives?
Fulgent Genetics' management team includes the folowing people:
- Mr. Ming Hsieh, Chairman, CEO & Pres (Age 63)
- Mr. Paul Kim, Chief Financial Officer (Age 52)
- Dr. Han Lin Gao, Chief Scientific Officer & Lab Director (Age 52)
When did Fulgent Genetics IPO?
(FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.
How do I buy shares of Fulgent Genetics?
Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Fulgent Genetics' stock price today?
One share of FLGT stock can currently be purchased for approximately $11.51.
How big of a company is Fulgent Genetics?
Fulgent Genetics has a market capitalization of $212.82 million and generates $21.36 million in revenue each year. The company earns $-5,610,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Fulgent Genetics employs 123 workers across the globe.View Additional Information About Fulgent Genetics.
What is Fulgent Genetics' official website?
How can I contact Fulgent Genetics?
Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE SUITE 205, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]
MarketBeat Community Rating for Fulgent Genetics (NASDAQ FLGT)
MarketBeat's community ratings are surveys of what our community members think about Fulgent Genetics and other stocks. Vote "Outperform" if you believe FLGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
